Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q2 2026 | ~2026-06-30 | $3.4600 |
| Q2 2025 | ~2025-06-30 | $3.0000 |
| Q2 2024 | ~2024-06-30 | $2.6000 |
| Q2 2023 | ~2023-06-30 | $2.2600 |
| Q2 2022 | ~2022-06-30 | $1.9600 |
| Q2 2021 | ~2021-06-30 | $1.7000 |
| Q3 2020 | ~2020-09-30 | $0.7400 |
| Q2 2020 | ~2020-06-30 | $0.7400 |
| Q2 2019 | ~2019-06-30 | $1.2900 |
| Q2 2018 | ~2018-06-30 | $0.5625 |
| Q1 2018 | ~2018-03-31 | $0.5625 |
| Q4 2017 | ~2017-12-30 | $0.5600 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Eli Lilly and Company is a leading global pharmaceutical company engaged in the discovery, development, and delivery of pharmaceutical products. The company discovers and develops… medicines across multiple therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro and Zepbound (for weight management and diabetes), Trulicity (for type 2 diabetes), Jardiance (for heart disease and type 2 diabetes), Verzenio (for breast cancer), and Taltz (for immunological conditions). The company operates through research and development, manufacturing, and commercialization of pharmaceutical products globally. Lilly also engages in partnerships and acquisitions to expand its pipeline and capabilities, including recent acquisitions in gene therapy and early-stage biotech. The company focuses on innovation, patient access, and sustainability, with manufacturing facilities worldwide and operations in major markets including the United States, Europe, Japan, and China.
- Name
- Eli Lilly and Company
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks · Chair, President and Chief Executive Officer
- Employees
- 37,800 as of 2025-12-31
- IPO Date
- 2021-08-13
- Phone
- (317) 276-2000
- Address
- Lilly Corporate Center, Indianapolis, IN 46285
- Website
- lilly.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Michael Harrington | Senior Vice President | — |
| Jan Lundberg | Senior Vice President, Chief Scientific Officer | — |
| Anat Hakim | Executive Vice President, General Counsel and Secretary | — |
| Kathleen Fish | Senior Vice President, Chief Financial Officer | — |
| David A. Ricks | Chair, President and Chief Executive Officer | — |
Latest News
-
2026-04-24
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 seekingalpha.com
- 2026-04-24
- 2026-04-24
- 2026-04-23
- 2026-04-21
- 2026-04-21
- 2026-04-21
-
2026-04-21
Eli Lilly and Company $LLY Shares Bought by CM Wealth Advisors LLC defenseworld.net